Clinical Trials Logo

Urinary Bladder Neoplasms clinical trials

View clinical trials related to Urinary Bladder Neoplasms.

Filter by:

NCT ID: NCT06109857 Recruiting - Hematuria Clinical Trials

Bladder Bank (a Prospective Banking Study)

Start date: July 6, 2022
Phase:
Study type: Observational

This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.

NCT ID: NCT06108492 Recruiting - Clinical trials for High-risk Non-muscle Invasive Bladder Cancer

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: November 28, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with high-risk non-muscle invasive bladder cancer.

NCT ID: NCT06100653 Recruiting - Clinical trials for Non-muscular Invasive Bladder Cancer

BCG for Therapeutic Use Phase I Clinical Trial

Start date: November 22, 2023
Phase: Phase 1
Study type: Interventional

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

NCT ID: NCT06092450 Recruiting - Bladder Cancer Clinical Trials

Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer

Start date: August 1, 2023
Phase:
Study type: Observational

Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis. This study was aimed to develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC.

NCT ID: NCT06091124 Recruiting - Bladder Cancer Clinical Trials

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

RJBLC-NEBC001
Start date: November 16, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: - The pathologic complete response rate at radical cystectomy - Safety and tolerability of combination therapy Participants will be treated with a combination therapy of adebrelimab, etoposide, and cisplatin before radical cystectomy, with a maximum of 4 cycles.

NCT ID: NCT06087016 Recruiting - Clinical trials for Urinary Bladder Tumour

Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers

MUSCADE
Start date: March 6, 2023
Phase:
Study type: Observational

This study aims to evaluate the performance of vibrational spectroscopy (Infrared and Raman spectroscopy techniques) in bladder cancer diagnosis using urine samples.

NCT ID: NCT06074484 Recruiting - Clinical trials for Muscle Invasive Bladder Carcinoma

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Start date: September 10, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with AK104 in perioperative treatment of muscle-invasive bladder cancer.

NCT ID: NCT06059547 Recruiting - Bladder Cancer Clinical Trials

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, stratified and single-blinded Phase 2 study of neoadjuvant immunotherapy in combination with the antiGDF15 antibody visugromab (CTL-002) for the treatment of subjects with MIBC set to undergo radical Cystectomy (RC) who cannot receive or refuse to receive cisplatin-based chemotherapy.

NCT ID: NCT06046469 Recruiting - Bladder Cancer Clinical Trials

Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The aim of this work is to compare validity between CT and MRI in detecting muscular invasion in Patients with bladder cancer.

NCT ID: NCT06040762 Recruiting - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients Receiving Chemotherapy Before Radical Cystectomy, Get Moving Trial

Start date: December 19, 2023
Phase: N/A
Study type: Interventional

Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline. This clinical trial evaluates the utility of a personalized home-based prehabilitation exercise intervention for the improvement of physical function and surgical outcomes in patients receiving chemotherapy before routine radical cystectomy for localized (non-metastatic) muscle-invasive bladder cancer. The exercise intervention includes at-home exercise sessions focused on the improvement of core strength and balance as well as personalized step count goals, delivered to patients remotely via a smart-device-based application (ExerciseRx). Encouraging physical activity before surgery may improve physical function and surgical outcomes in patients who are scheduled to undergo surgery for their non-metastatic muscle-invasive bladder cancer.